Showing 7881-7890 of 9757 results for "".
- New Study From Valisure Extends Previous Research on Benzoyl Peroxide Productshttps://practicaldermatology.com/news/study-benzene-risks-common-benzoyl-peroxide-products/2468369/A new study conducted by Valisure has raised concern about benzene contamination in benzoyl peroxide (BPO) drug products used for acne and rosacea treatment. Among 111 tested BPO products, 34% contained benzene concentrations exceeding the FDA's conditional limit of 2 parts per million (pp
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,
- New Deuruxolitinib Data to Be Presented at EADVhttps://practicaldermatology.com/news/new-deuruxolitinib-data-be-presented-eadv/2468304/Sun Pharma will present new clinical data on the JAK1/JAK2 inhibitor deuruxolitinib at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands from September 25-28, the company announced. Deuruxolitinib, which Sun Pharma provides under the name LE
- IGSRT Shows High Recurrence-Free Rates in Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/igsrt-shows-high-recurrence-free-rates-non-melanoma-skin-cancer/2468185/Nonmelanoma skin cancer (NMSC) treated with Image-Guided Superficial Radiation Therapy (IGSRT) showed consistently high freedom from recurrence rates, regardless of patient age or sex, according to a new analysis. The large retrospective cohort study, published in Geriatrics and c
- Timber Pharmaceuticals Fails Phase 3 Trial for Congenital Ichthyosis Drug Candidatehttps://practicaldermatology.com/news/timber-pharmaceuticals-fails-phase-3-trial-congenital-ichthyosis-drug-candidate/2467911/LEO Pharma's subsidiary, Timber Pharmaceuticals, failed a late-stage trial for its investigational topical ointment formulation of isotretinoin for treating moderate to severe congenital ichthyosis. The phase 3 ASCEND trial was 12-week randomized, double-blind clinical study evaluating TM
- Quitting Smoking Reduces Hidradenitis Suppurativa Riskhttps://practicaldermatology.com/news/quitting-smoking-reduces-hidradenitis-suppurativa-risk/2467901/A new study suggests that smoking cessation is associated with reduced risk of developing hidradenitis suppurativa (HS). Researchers for the population-based cohort study looked at the relationship between the change in smoking habits and the incidence of HS in more than 6 million partic
- Topical Skin Introduces Hydrating Facial Cleanserhttps://practicaldermatology.com/news/topical-skin-introduces-hydrating-facial-cleanser/2467858/Topical Skin announced the launch of the Hydrating Facial Cleanser, formulated with ceramide, botanicals, and oleosomes and designed to provide a gentle yet effective cleanse while supporting the skin's barrier, resulting in a hydrated and refreshed complexion. Unlike some cleansers that
- Genome-Wide Study Reveals Genetic Correlation Between Melanoma Subtypeshttps://practicaldermatology.com/news/genome-wide-study-reveals-genetic-correlation-between-melanoma-subtypes/2467851/Data from a recent genome-wide association study (GWAS) looking at the genetic underpinnings of in situ and invasive melanoma show significant shared genetic architecture between the two. Researchers for the study used data from four population-based genetic cohorts, including the UK Bio
- Tildrakizumab Shows Efficacy in Plaque Psoriasishttps://practicaldermatology.com/news/tildrakizumab-shows-significant-efficacy-plaque-psoriasis/2467713/Tildrakizumab was associated with improvements in disease severity in patients with moderate-to-severe plaque psoriasis, according to results from a new study in the Journal of Drugs in Dermatology. Researchers for the phase 4, multicenter, uncontrolled, open-label trial enrolle
- Consensus Statement: New Reporting Measures Aim to Improve CSCC Researchhttps://practicaldermatology.com/news/consensus-statement-new-reporting-measures-aim-improve-cscc-research/2467669/A new consensus statement from an expert panel supports the creation of standardized guidelines for retrospective studies on cutaneous squamous cell carcinoma (CSCC). "Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology a